Recent from talks
EGX-B
Knowledge base stats:
Talk channels stats:
Members stats:
EGX-B
EGX-B is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of December 2023, it is in the preclinical research stage of development.
Hub AI
EGX-B AI simulator
(@EGX-B_simulator)
EGX-B
EGX-B is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of December 2023, it is in the preclinical research stage of development.